

### RÉFÉRENCES GÉNÉRALES

#### LIGNES DIRECTRICES

- 1- *NICE guidelines*- Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer- Mars 2017, Last updated November 2019
- 2- *American Society of Breast Surgeons* – Consensus Guideline on Hereditary Genetic Testing for Patients With and Without Breast Cancer – february 2019
- 3- *Society of Gynecologic Oncology Canada* - Optimiser le dépistage des mutations des gènes brca dans le contexte du cancer de l’ovaire -2018
- 4- *Cancer Care Ontario/Magnetic Resonance Imaging Screening of Women at High Risk for Breast Cancer*- Janvier 2018
- 5- *MSSS*- Recommandations sur l’utilisation de l’IRM dans le diagnostic et le traitement du cancer du sein et pour la surveillance active chez les femmes à risque- 2016
- 6- *ACMG- practice guidelines 2015*
- 7- *NCCN Guidelines Version 1.2020- Breast Cancer Screening and Diagnosis*- September 17, 2020 ® © National Comprehensive Cancer Network, Inc. 2020
- 8- *NCCN Guidelines Version 2.2021 Genetic/Familial High-Risk Assessment: Breast, Ovarian and Pancreatic* – November 20, 2020 ® © National Comprehensive Cancer Network, Inc. 2020
- 9- *NCCN version 1.2020 Breast Cancer Risk Reduction* May 29, 2020 © National Comprehensive Cancer Network, Inc. 2020
- 10- *NCCN version 1.2021 Breast Cancer* January 15, 2021 © National Comprehensive Cancer Network, Inc. 2021
- 11- *NCCN Guidelines Version 1.2020- Genetic/Familial High-Risk Assessment: Colorectal*- July 21,2020, © National Comprehensive Cancer Network, Inc. 2020
- 12- *INCA –France – Les consultations d’oncogénétique* -2019, Le point sur les prédispositions génétiques liées aux cancers du sein et/ou de l’ovaire – 2017, Prise en charge et Chirurgies prophylactiques - avril 2009
- 13- *BC Cancer 2021* - <http://www.bccancer.bc.ca/health-professionals/clinical-resources/hereditary-cancer#Syndromes>
- 14- *Australia* - [www.eviq.org.au](http://www.eviq.org.au) consulté février 2021
- 15- *Cancer care Ontario* : nom changé en 2021
- 16- *Alberta Health Services*- 2011 et 2012
- 17- *Annals of Oncology* 27 (Supplement 5): v103–v110, 2016, *S. Paluch-Shimon, F. Cardoso, C. Sessa, J. Balmana, M. J. Cardoso, F. Gilbert & E. Senkus, on behalf of the ESMO Guidelines Committee*, Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening

- 18- Current Oncology, [Vol 23, No 6 \(2016\)](#) - J. Gagnon, E. Lévesque, *the Clinical Advisory Committee on Breast Cancer Screening and Prevention*, B.M. Knoppers, J Simard, Recommendations on breast cancer screening and prevention in the context of implementing risk stratification: impending changes to current policies
- 19- Management of Male Breast Cancer: ASCO guideline, Michael J Hasset and al, J Clin Oncol 38:1849-1863. © 2020 by American Society of Clinical Oncology
- 20- Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline, Nadine M Tung and al, J Clin Oncol 38:2080-2106. © 2020 by American Society of Clinical Oncology
- 21- Updated Breast Cancer Surveillance Recommendations for Female Survivors of Childhood, Adolescent, and Young Adult Cancer From the International Guideline Harmonization Group, Renée L. Mulder and al., J Clin Oncol 38:4194-4207. © 2020 by American Society of Clinical Oncology
- 22- Clinical Practice Guideline, ASTRO Radiation Therapy Summary of the ASCO-ASTRO-SSO Guideline on Management of Hereditary Breast Cancer, Mark G. Trombetta and al, Practical Radiation Oncology® (2020) 10, 235-242

### NOUVEAUX ARTICLES GÈNES 2021

- 23- A Population-Based Study of Genes Previously Implicated in Breast Cancer C. Hu and al, NEJM February 4, 2021
- 24- Breast Cancer Risk Genes — Association Analysis in More than 113,000 Women, Breast Cancer Association Consortium (BCAC), Doug Easton and al, NEJM February 4, 2021
- 25- Which Genes for Hereditary Breast Cancer? Steven A. Narod, M.D. This editorial was published on January 20, 2021, at NEJM.org.

### CANCER TRIPLE NÉGATIF

- 26- Clin Cancer Res. 2011 Mar 1;17(5):1082-9. Gonzalez-Angulo AM et al Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer.
- 27- NGS Panel Testing of Triple-Negative Breast Cancer Patients in Cyprus: A Study of BRCA-Negative Cases, Maria Zanti, Cancers 2020, 12, 3140; doi:10.3390/cancers12113140
- 28- Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing, Hermela Shimelis,.....Fergus Couch, JNCI J Natl Cancer Inst (2018) 110(8): djy106
- 29- Evaluation of BRCA1/2 mutational status among German and Austrian women with triple-negative breast cancer, Axel Muendlein and al, J Cancer Res Clin Oncol 2015 DOI 10.1007/s00432-015-1986-2 - Published: 15 May 2015
- 30- ANN SURG ONCOL 2013 Oct;20(10):3254-8. doi: 10.1245/s10434-013-3205-1. Epub 2013 Aug 22. Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort Rachel Greenup 1, Adam Buchanan, Wendy Lorizio, Keelia Rhoads, Salina Chan, Tracey Leedom, Robin King, Jane McLennan, Beth Crawford, P Kelly Marcom, E Shelley Hwang PMID: 23975317 DOI: 10.1245/s10434-013-3205-1

#### PRISE EN CHARGE HISTOIRE FAMILIALE

- 31- Can Fam Physician 2016;62:e572-7 - Ruth Heisey MD, June C. Carroll MD Identification et prise en charge des femmes ayant des antécédents familiaux de cancer du sein
- 32- World J Surg (2010) 34: 979-986 , Muller J, Cockburn L, Joshua H, Thorley G, Baker C, Wood N, Brazier J, Jones M, Dunn N, Gattas M. Outcomes of multimodality breast screening for women at increased risk of familial breast cancer.

#### DÉPISTAGE TRANSGENRES

- 33- Cancer screening in the transgender population: a review of current guidelines, best practices, and a proposed care model, Joshua Sterling and al, Transl Androl Urol 2020;9(6):2771-2785
- 34- Breast Imaging of Transgender Individuals: A Review Emily B. Sonnenblick and al, Curr Radiol Rep (2018) 6:1 , p1-12
- 35- Breast cancer risk and breast screening for trans people: an integration of 3 systematic reviews, Olivia Meggetto and al, CMAJ OPEN 2018, 7(3) ,E598-E609,
- 36- Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands Christel J M de Blok and al, BMJ 2019;365:l1652

#### DÉPISTAGE CANCER SEIN PERSONNES À RISQUE

- 37- JNCI J Natl Cancer Inst (2020) 112(4): djz131 Annual vs Biennial Screening: Diagnostic Accuracy Among Concurrent Cohorts Within the Ontario Breast Screening Program, Anna M. Chiarelli and al,
- 38- Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline, Nadine M Tung and al, J Clin Oncol 38:2080-2106. © 2020 by American Society of Clinical Oncology
- 39- Protocols for surveillance of women at very high risk of developing breast cancer - GOV.UK Updated 5 November 2020 © Crown copyright 2020  
<https://www.gov.uk/government/publications/breast-screening-higher-risk-women-surveillance-protocols>
- 40- Performance Measures of Magnetic Resonance Imaging Plus Mammography in the High Risk Ontario Breast Screening Program , Anna M. Chiarelli and al, JNCI J Natl Cancer Inst (2020) 112(2)

#### DÉPISTAGE CANCER SEIN HOMMES

- 41- Breast Cancer Screening in High-Risk Men: A 12-year Longitudinal Observational Study of Male Breast Imaging Utilization and Outcomes, Gao Y, et al Radiology 2019;293:282-291.
- 42- JAMA Oncol 2020 :6(8) :1218-1230, Characterization of the cancer spectrum in men with germlineBRCA1 and BRCA2 pathogenic variants- Results from the Consortium of Investigators of modifiers of BRCA1/2 (CIMBA), Valentina Silvestri and al

- 43- Management of Male Breast Cancer: ASCO guideline, Michael J Hasset and al, J Clin Oncol 38:1849-1863. © 2020 by American Society of Clinical Oncology
- 44- Breast Cancer Screening in High-Risk Men: A 12-year Longitudinal Observational Study of Male Breast Imaging Utilization and Outcomes ,Yiming Gao,MD and al (165 hommes avec 271 mammos dépistage dans la cohorte),Radiology 2019; 293:282–291
- 45- Image-Based Screening for Men at High Risk for Breast Cancer: Benefits and Drawbacks, Ryan W. Woods, Clin Imaging. 2020 March ; 60(1): 84–89
- 46- Male Breast Cancer Risk Assessment and Screening Recommendations in High-Risk Men Who Undergo Genetic Counseling and Multigene Panel Testing , Sushma Gaddam and al , Clinical Breast Cancer February 2021 e74-e79-
- 47- Clinical Indications for Mammography in Men and Correlation With Breast Cancer, Kyungmin Shin, MD and al, Current Problems in Diagnostic Radiology 000 (2020) 17

### DENSITÉ MAMMAIRE

- 48- MINISTÈRE DE LA SANTÉ ET DES SERVICES SOCIAUX. *Dépistage et cancer du sein : Densité mammaire. Module de formation à l'intention des professionnels de première ligne*, Québec, 2018, 17 p
- 49- Interval Breast Cancer Rates and Tumor Characteristics in Malmö Breast Tomosynthesis Screening Trial, Johnson et al, Radiology.rsna.org n Radiology: Volume 000: Number 0— Month 2021
- 50- Screening Performance of Digital Breast Tomosynthesis vs Digital Mammography in Community Practice by Patient Age, Screening Round, and Breast Density, Kathryn P. Lowry, MD1; Rebecca Yates Coley, PhD2; Diana L. Miglioretti, PhD2,3; et al, JAMA Network Open. 2020;3(7): e2011792.
- 51- JNCI J Natl Cancer Inst (2020) 112(4): djz131 Annual vs Biennial Screening: Diagnostic Accuracy Among Concurrent Cohorts Within the Ontario Breast Screening Program, Anna M. Chiarelli and al.
- 52- Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection in Women With Dense Breasts, Christopher E. Comstock, MD and al, JAMA February 25, 2020 Volume 323, Number 8

### DÉPISTAGE et ATCD RADIOTHÉRAPIE

- 53- Clinical Benefits, Harms, and Cost-Effectiveness of Breast Cancer Screening for Survivors of Childhood Cancer Treated With Chest Radiation A Comparative Modeling Study, Jennifer M. Yeh and al, Ann Intern Med. 2020;173:331-341. doi:10.7326/M19-3481
- 54- Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers COG LTFU Guidelines Version 5.0 – October 2018
- 55- Updated Breast Cancer Surveillance Recommendations for Female Survivors of Childhood, Adolescent, and Young Adult Cancer From the International Guideline Harmonization Group, Renée L. Mulder and al., J Clin Oncol 38:4194-4207. © 2020 by American Society of Clinical Oncology

- 56-** Clinical Practice Guideline, ASTRO Radiation Therapy Summary of the ASCO-ASTRO-SSO Guideline on Management of Hereditary Breast Cancer, Mark G. Trombetta and al ,Practical Radiation Oncology® (2020) 10, 235-242

#### GADOLINIUM

- 57-** J AM Coll Radiol- 2020 Apr;17(4):546-550, Gadolinium DepositionDisease: A New Risk Management Threat, H Benjamin Harvey and al

#### FACTEURS DE RISQUE

- 58-** J Natl Cancer Inst 2020 May 2, Combined associations of a polygenic risk score and classical risk factors with breast cancer risk
- 59-** JAMA Network Open. 2020;3(4):e203760. doi:10.1001/jamanetworkopen.2020.3760 , Association of Nongenetic Factors With Breast Cancer Risk in Genetically Predisposed Groups of Women in the UK Biobank Cohort, Kawthar Al Ajmi, and al

#### MUTATIONS ET RADIOTHÉRAPIE

- 60-** Clinical Practice Guideline, ASTRO Radiation Therapy Summary of the ASCO-ASTRO-SSO Guideline on Management of Hereditary Breast Cancer, Mark G. Trombetta and al ,Practical Radiation Oncology® (2020) 10, 235-242
- 61-** JAMA Network Open. 2020;3(4):e203760. doi:10.1001/jamanetworkopen.2020.3760 , Association of Nongenetic Factors With Breast Cancer Risk in Genetically Predisposed Groups of Women in the UK Biobank Cohort, Kawthar Al Ajmi, and al

#### LI-FRAUMENI

- 62-** Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome, Clin Cancer Res; 23(11); e38–e45. ©2017 AACR
- 63-** Hanson H, Brady AF, Crawford G Consensus Group Members, et al, UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants , Journal of Medical Genetics 2021; 58:135-139.
- **Voir aussi** références citées dans le Tableau récapitulatif pour le dépistage des personnes avec syndrome de Li-Fraumeni *dans les annexes*
  - **Voir aussi** référence 17

#### RÉFÉRENCES SPÉCIFIQUES de la DRE MARIE PLANTE

- 1- Bennett IC, Muller J, Cockburn L, Joshua H, Thorley G, et al. (2010) Outcomes of multimodality breast screening for women at increased risk of familial breast cancer. *World J Surg* 34: 979-986.
- 2- Zakhour M, Danovitch Y, Lester J, Rimel BJ, Walsh CS, et al. (2016) Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers. *Gynecol Oncol* 143: 231-235.
- 3- Ayres C, Ratnayake G, McNally O, Quinn M (2017) Challenging Salpingectomy as a Risk-Reducing Measure for Ovarian Cancer: Histopathological Analysis of the Tubo-Ovarian Interface in Women Undergoing Risk-Reducing Salpingo-oophorectomy. *Int J Gynecol Cancer* 27: 703-707.
- 4- Havrilesky LJ, Moss HA, Chino J, Myers ER, Kauff ND (2017) Mortality reduction and cost-effectiveness of performing hysterectomy at the time of risk-reducing salpingo-oophorectomy for prophylaxis against serous/serous-like uterine cancers in BRCA1 mutation carriers. *Gynecol Oncol* 145: 549-554.
- 5- Shu CA, Pike MC, Jotwani AR, Friebel TM, Soslow RA, et al. (2016) Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. *JAMA Oncol* 2: 1434-1440.
- 6- Pujade-Lauraine E, Ledermann JA, Selle F, GebSKI V, Penson RT, et al. (2017) Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Oncol* 18: 1274-1284.
- 7- Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, et al. (2018) Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. *N Engl J Med* 379: 2495-2505.

#### NOUVEAUX ARTICLES 2021

- 8- M. Hickey, K.M. Moss, A. Brand, et al., What happens after menopause? (WHAM): A prospective controlled study of depression and anxiety up to..., *Gynecologic Oncology*, <https://doi.org/10.1016/j.ygyno.2021.02.001>
- 9- Sanne W. ten Broeke , and al, Cancer Risks for PMS2-Associated Lynch Syndrome, *J Clin Oncol* 36:2961-2968. © 2018
- 10- C. Nahshon, Y. Segev, O. Gerner, et al., Should the risk for uterine cancer influence decision making for prophylactic hysterectomy in BRCA1/..., *Gynecologic Oncology*, <https://doi.org/10.1016/j.ygyno.2020.11.034>

### RÉFÉRENCES SITES WEB

#### SITES CONSULTÉS FÉVRIER À MAI 2021 :

- 1- <https://www.eviq.org.au/cancer-genetics/adult>
- 2- [www.etudeperspective.ca](http://www.etudeperspective.ca)
- 3- [www.depistagesein.ca](http://www.depistagesein.ca)
- 4- <https://www.gov.uk/government/publications/breast-screening-higher-risk-women-surveillance-protocols>
- 5- <https://www.nice.org.uk/guidance/CG164>
- 6- <https://www.fda.gov/Drugs/DrugSafety/ucm559007.htm>
- 7- [https://www.nccn.org/professionals/physician\\_gls/default.aspx](https://www.nccn.org/professionals/physician_gls/default.aspx)
- 8- <https://www.asco.org/research-guidelines/quality-guidelines/guidelines/breast-cancer#/143725>
- 9- <https://www.asco.org/research-guidelines/quality-guidelines/guidelines/breast-cancer#/142881>
- 10- <http://www.bccancer.bc.ca/screening/Documents/Breast-Density-Discussion-Guide.pdf>
- 11- <http://www.bccancer.bc.ca/health-professionals/clinical-resources/hereditary-cancer#Syndromes>
- 12- <https://www.e-cancer.fr/Professionnels-de-sante/Recommandations-et-outils-d-aide-a-la-pratique/Oncogenetique-ou-Cancers-avec-predispositions-genetiques>
- 13- <https://www.e-cancer.fr/Professionnels-de-sante/Depistage-et-detection-precoce/Depistage-du-cancer-du-sein/Orienter-vos-patientes>
- 14- [https://www.has-sante.fr/jcms/p\\_3148278/fr/evaluation-de-la-performance-et-de-la-place-de-la-mammographie-par-tomosynthese-dans-le-programme-national-de-depistage-organise-du-cancer-du-sein-volet-2-note-de-cadrage](https://www.has-sante.fr/jcms/p_3148278/fr/evaluation-de-la-performance-et-de-la-place-de-la-mammographie-par-tomosynthese-dans-le-programme-national-de-depistage-organise-du-cancer-du-sein-volet-2-note-de-cadrage)
- 15- <https://healthcare-quality.jrc.ec.europa.eu/european-breast-cancer-guidelines>